Duration of Shingrix Protection
Shingrix provides protection against herpes zoster for at least 10-11 years, with vaccine efficacy remaining above 73% at 10 years and above 80% at 11 years post-vaccination. 1, 2
Evidence for Long-Term Protection
The most robust data comes from long-term follow-up of the pivotal ZOE-50 and ZOE-70 trials:
- Persistence of protection was maintained above 83.3% for up to 8 years 1
- Efficacy decreased to 73% at 10 years 1, 2
- Recent evidence shows efficacy persists above 80% for 11 years 3
This represents a substantial improvement over the older live zoster vaccine (Zostavax), which showed significant waning with efficacy dropping from 51.3% to 21.2% for herpes zoster incidence during 7-11 years post-vaccination 1.
Clinical Implications
No booster doses are currently recommended or required. The two-dose series (given 2-6 months apart, or 1-2 months apart in immunocompromised individuals) provides durable protection for over a decade 1, 4.
Key Points:
- The vaccine maintains clinically meaningful protection (>70%) for at least 10-11 years
- Real-world effectiveness studies confirm sustained protection, with 73% effectiveness after 4 years in observational data 5
- Protection against complications like postherpetic neuralgia also remains robust over time 1
Important Caveat:
While 10-11 years represents the longest follow-up data currently available, this does not mean protection ends at 11 years—it simply reflects the duration of available study data. Ongoing surveillance will determine if and when booster doses might eventually be needed.